Search
Research
A Phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infants (NeXXstep)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
OPTIMUM: OPTimising IMmunisation Using Mixed schedulesPat Peter Susan Tom Jennifer Holt Richmond Prescott Snelling Kent PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP MBBS BMedSci PhD FRACP BMBS DTMH
Research
Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in AustraliaOur population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection
Research
Using record linkage to validate notification and laboratory data for a more accurate assessment of notifiable infectious diseasesStudies investigating pathogen-specific infectious disease would benefit from using multiple data sources.
Research
Influenza-Associated Encephalitis/Encephalopathy Identified by the Australian Childhood Encephalitis Study 2013-2015We aimed to describe case of Influenza associated encephalitis/encephalopathy identified by the Australian Childhood Encephalitis study
Research
Otitis-prone children produce functional antibodies to pneumolysin and pneumococcal polysaccharidesThe production of functional antipneumococcal antibodies in otitisprone children demonstrates that they respond to the current pneumococcal conjugate vaccine (PCV)and are likely to respond to pneumolysin-based vaccines as effectively as healthy children.
Research
‘Is it like one of those infectious kind of things?’ The importance of educating young people about HPV and HPV vaccination at schoolGreater knowledge and understanding of National Human Papillomavirus vaccination appeared to promote positive attitudes towards vaccination
Research
Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccinationWe studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in children, 3-5 years of age, in community controls of a similar age.
Research
No evidence for impaired humoral immunity to pneumococcal proteins in Australian Aboriginal children with otitis mediaConserved vaccine candidate proteins from S.pneumoniae induce serum and salivary antibody responses in Aboriginal and non-Aboriginal children with history of OM
Research
Influenza vaccine effectiveness and uptake in children at risk of severe diseaseParticipation in the preschool influenza vaccination program remains low with parents unconvinced of the benefits and safety of influenza vaccine